Cancer treatment firm plans to open Indianapolis plant, hire 113
The company is one of many across the globe in a mad rush to develop radioligand therapies for cancer treatment—a field that’s expected to see explosive growth.
Pharmaceutical
Articles
Pandemic hobbles drugmakers in recruiting for new studies
The Covid-19 pandemic is hampering research across the pharmaceutical industry, including at Indianapolis-based Eli Lilly and Co.
Coronavirus patients rush to join studies of Gilead drug
Remdesivir is farther along in testing than many other potential therapies, and the current studies could lead to regulatory approval.
Lilly teams with British startup to develop autoimmune medicines
In a deal that could eventually be worth close to a billion dollars, Eli Lilly and Co. is teaming with a British biopharmaceutical company in one of the hottest areas in medical research.
FDA authorizes widespread use of unproven drugs to treat coronavirus
The Food and Drug Administration has given emergency approval to a plan to distribute millions of doses of anti-malarial drugs to hospitals across the country, saying it is worth the risk of trying unproven treatments to slow the progression of the disease in seriously ill coronavirus patients.
Karuna Therapeutics, led by former Lilly research leader, opens Carmel office
Karuna Therapeutics Inc., a publicly traded biopharmaceutical company, is developing a potential blockbuster treatment for schizophrenia that got its start at Eli Lilly and Co. decades ago.
Potential coronavirus treatment granted rare disease status
Experts who have studied the so-called “orphan drug” program say the company’s request—and the FDA’s decision to grant it—seem inappropriate given the rapidly expanding threat of the viral outbreak. A financial analyst, though, called Gilead’s request “pretty standard.”
Lilly teams with Canadian biotech in race to find treatment for COVID-19
The Indianapolis-based drugmaker said it will combine its capability for quickly developing antibodies with AbCellera’s “rapid pandemic response platform,” with the goal of getting a treatment into clinics for human testing within four months.
Frustrated health consumers turn to apps, websites to find lowest drug prices
In recent years, a host of online websites and smartphone apps—such as GoodRx, Blink Health and Script Saver—have popped up to help people find the lowest price for prescription medicines. By using them, consumers can save thousands of dollars a year on their prescriptions if they don’t mind shopping around and buying some of their drugs outside their insurance plans.
Lilly reports strong fourth quarter on rising sales of Trulicity, Taltz
The Indianapolis-based drugmaker exceeded analyst expectations for both profit and revenue during the most recent quarter.
Lilly to build $470M manufacturing plant in North Carolina
Eli Lilly and Co. said it considered sites in Indianapolis and Pennsylvania but chose North Carolina for quality of life, cost of operations and geographical diversity.
Lilly adding two more insulin options to discount program
Under fire over insulin prices, the Indianapolis-based drugmaker said Tuesday morning it is introducing lower-priced versions of its Humalog KwikPen and Humalog Junior KwikPen.
$1.1B acquisition would give Lilly more skin in immunology game
Analysts have said that Dermira’s lead pipeline product, lebrikizumab, has the potential to be the best in class among a wave of similar antibodies to treat eczema.
North America trade pact contains rare setback for Big Pharma
To satisfy House Democrats, the Trump administration removed a provision that would have given the makers of ultra-expensive biologic drugs 10 years of protection from less expensive knockoffs.
House passes bill to empower Medicare to negotiate drug costs
The legislation has no chance of passing the Republican-controlled Senate, and the White House has issued a veto threat. Still, Democrats saw a victory in the message their bill sends to voters.
U.S. report: Prescription drug prices down slightly last year
Though modest, it was the first such price drop in 45 years, according to nonpartisan economic experts at the federal Department of Health and Human Services, who deliver an annual report on the nation’s health care spending.
Pelosi sets Medicare showdown on drug costs, new benefits
As a hammer to force companies to negotiate, House Speaker Nancy Pelosi would impose steep sales taxes on the medications at issue. Overall, budget analysts estimated the legislation would cut industry revenues by $500 billion to $1 trillion over 10 years.
Medicare drug plan finder can steer seniors to higher costs
As open enrollment goes into the home stretch Thanksgiving week, critics say the new tool can create confusion by obscuring out-of-pocket costs that seniors should factor into their decisions.
Eli Lilly to spend $400M on manufacturing expansion in Indy, add 100 jobs
The pharmaceutical giant says it needs additional manufacturing capacity to keep up with demand for current medicines and new drugs expected to emerge from its pipeline.
White House urgently ramps up push for drug cost legislation
A Gallup-West Health poll finds that 66 percent of adults don’t believe the Trump administration has made any progress, or very much progress, in limiting the rising cost of prescription drugs.